Video

Novel Excipients Versus Active Substances And Inflammatory Response

Novel excipients or active substances? In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, Christian Dohmen, Senior Director of Formulation & Aerosol Research at Ethris, and Patrick Baumhof, SVP of Technology at CureVac address the debate and discuss LNP-related inflammatory response concerns.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Roche CustomBiotech